1. Home
  2. APRE vs SST Comparison

APRE vs SST Comparison

Compare APRE & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$1.86

Market Cap

12.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
SST
Founded
2006
2013
Country
United States
United States
Employees
N/A
250
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
12.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
APRE
SST
Price
$0.63
$1.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$4.10
$10.00
AVG Volume (30 Days)
57.0K
81.1K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$1.35
52 Week High
$1.93
$9.30

Technical Indicators

Market Signals
Indicator
APRE
SST
Relative Strength Index (RSI) 40.85 37.41
Support Level $0.57 $1.35
Resistance Level $0.83 $4.71
Average True Range (ATR) 0.06 0.23
MACD -0.01 -0.04
Stochastic Oscillator 34.44 36.30

Price Performance

Historical Comparison
APRE
SST

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

Share on Social Networks: